KR20260040657A - 테트라히드로피라졸로-피라지닐-디히드로이미다졸론 또는 테트라히드로피라졸로-피리디닐-디히드로이미다졸론 화합물 및 그의 사용 방법 - Google Patents

테트라히드로피라졸로-피라지닐-디히드로이미다졸론 또는 테트라히드로피라졸로-피리디닐-디히드로이미다졸론 화합물 및 그의 사용 방법

Info

Publication number
KR20260040657A
KR20260040657A KR1020267006827A KR20267006827A KR20260040657A KR 20260040657 A KR20260040657 A KR 20260040657A KR 1020267006827 A KR1020267006827 A KR 1020267006827A KR 20267006827 A KR20267006827 A KR 20267006827A KR 20260040657 A KR20260040657 A KR 20260040657A
Authority
KR
South Korea
Prior art keywords
butyl
alkyl
butoxy
compound
propyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020267006827A
Other languages
English (en)
Korean (ko)
Inventor
짜이팡 런
쉐펑 쑨
징예 저우
Original Assignee
에코진 인크.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 에코진 인크. filed Critical 에코진 인크.
Publication of KR20260040657A publication Critical patent/KR20260040657A/ko
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
KR1020267006827A 2020-07-20 2021-07-20 테트라히드로피라졸로-피라지닐-디히드로이미다졸론 또는 테트라히드로피라졸로-피리디닐-디히드로이미다졸론 화합물 및 그의 사용 방법 Pending KR20260040657A (ko)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
CNPCT/CN2020/102955 2020-07-20
CN2020102955 2020-07-20
CNPCT/CN2021/070120 2021-01-04
CN2021070120 2021-01-04
PCT/CN2021/107216 WO2022017338A1 (en) 2020-07-20 2021-07-20 Tetrahydropyrazolo-pyrazinyl-dihydroimidazolone or tetrahydropyrazolo-pyridinyl-dihydroimidazolone compounds and methods of using same
KR1020237005845A KR102936860B1 (ko) 2020-07-20 2021-07-20 테트라히드로피라졸로-피라지닐-디히드로이미다졸론 또는 테트라히드로피라졸로-피리디닐-디히드로이미다졸론 화합물 및 그의 사용 방법

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
KR1020237005845A Division KR102936860B1 (ko) 2020-07-20 2021-07-20 테트라히드로피라졸로-피라지닐-디히드로이미다졸론 또는 테트라히드로피라졸로-피리디닐-디히드로이미다졸론 화합물 및 그의 사용 방법

Publications (1)

Publication Number Publication Date
KR20260040657A true KR20260040657A (ko) 2026-03-25

Family

ID=77167918

Family Applications (2)

Application Number Title Priority Date Filing Date
KR1020267006827A Pending KR20260040657A (ko) 2020-07-20 2021-07-20 테트라히드로피라졸로-피라지닐-디히드로이미다졸론 또는 테트라히드로피라졸로-피리디닐-디히드로이미다졸론 화합물 및 그의 사용 방법
KR1020237005845A Active KR102936860B1 (ko) 2020-07-20 2021-07-20 테트라히드로피라졸로-피라지닐-디히드로이미다졸론 또는 테트라히드로피라졸로-피리디닐-디히드로이미다졸론 화합물 및 그의 사용 방법

Family Applications After (1)

Application Number Title Priority Date Filing Date
KR1020237005845A Active KR102936860B1 (ko) 2020-07-20 2021-07-20 테트라히드로피라졸로-피라지닐-디히드로이미다졸론 또는 테트라히드로피라졸로-피리디닐-디히드로이미다졸론 화합물 및 그의 사용 방법

Country Status (16)

Country Link
US (3) US12037339B2 (cg-RX-API-DMAC7.html)
EP (1) EP4182020A1 (cg-RX-API-DMAC7.html)
JP (3) JP7569443B2 (cg-RX-API-DMAC7.html)
KR (2) KR20260040657A (cg-RX-API-DMAC7.html)
CN (8) CN122516177A (cg-RX-API-DMAC7.html)
AU (2) AU2021311567B2 (cg-RX-API-DMAC7.html)
BR (1) BR112023000932A2 (cg-RX-API-DMAC7.html)
CA (1) CA3186217A1 (cg-RX-API-DMAC7.html)
CL (1) CL2023000196A1 (cg-RX-API-DMAC7.html)
CO (1) CO2023001407A2 (cg-RX-API-DMAC7.html)
IL (2) IL299704B1 (cg-RX-API-DMAC7.html)
MX (1) MX2023000943A (cg-RX-API-DMAC7.html)
PE (1) PE20230854A1 (cg-RX-API-DMAC7.html)
PH (1) PH12023550130A1 (cg-RX-API-DMAC7.html)
UA (1) UA130727C2 (cg-RX-API-DMAC7.html)
WO (1) WO2022017338A1 (cg-RX-API-DMAC7.html)

Families Citing this family (73)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JOP20190060A1 (ar) 2016-09-26 2019-03-26 Chugai Pharmaceutical Co Ltd مشتق بيرازولو بيريدين له تأثير مساعد لمستقبل glp-1
WO2022052958A1 (en) * 2020-09-10 2022-03-17 Gasherbrum Bio, Inc. Heterocyclic glp-1 agonists
US12643905B2 (en) 2021-07-23 2026-06-02 Enanta Pharmaceuticals, Inc. Spiropyrrolidine derived antiviral agents
US12479854B2 (en) 2021-07-29 2025-11-25 Enanta Pharmaceuticals, Inc. Spiropyrrolidine derived antiviral agents
US20240366639A1 (en) * 2021-08-12 2024-11-07 Gasherbrum Bio, Inc. Heterocyclic glp-1 agonists
SI4408840T1 (sl) 2021-09-27 2025-12-31 Terns Pharmaceuticals, Inc. Benzimidazolne karboksilne kisline kot agonisti GLP-1R
US12024507B2 (en) 2021-10-25 2024-07-02 Terns Pharmaceuticals, Inc. Compounds as GLP-1R agonists
AU2023224854A1 (en) 2022-02-23 2024-10-03 Terns Pharmaceuticals, Inc. Compounds as glp-1r agonists
PE20250009A1 (es) * 2022-05-11 2025-01-07 Lilly Co Eli Composiciones de comprimidos de glp1
CN118791482B (zh) * 2022-11-20 2025-09-09 药康众拓(北京)医药科技有限公司 一种氘代吲唑类化合物、药物组合物及其应用
IL321043A (en) * 2022-12-15 2025-07-01 Sironax Ltd SARM1 modulators, their preparations and uses
IL321472A (en) * 2022-12-19 2025-08-01 Lilly Co Eli Process for the production of GLP1 RA and intermediates therefor
US20260217707A1 (en) * 2023-01-17 2026-07-30 Fochon Biosciences, Ltd. Glp-1r agonists and uses thereof
KR20250168210A (ko) 2023-02-16 2025-12-02 가셔브룸 바이오, 인크. 헤테로시클릭 glp-1 효능제
PE20252787A1 (es) 2023-04-07 2025-12-22 Terns Pharmaceuticals Inc Combinacion que comprende un agonista de thr-beta y un agonista de glp-1r para su uso en el tratamiento de un trastorno hepatico o una enfermedad cardiometabolica
CN119630663B (zh) * 2023-06-29 2025-10-21 韦恩生物科技有限公司 一种glp-1受体激动剂及其制备方法和用途
TW202506108A (zh) * 2023-06-30 2025-02-16 大陸商正大天晴藥業集團股份有限公司 含多稠環結構的化合物
WO2025011664A1 (zh) 2023-07-12 2025-01-16 歌礼制药(中国)有限公司 Glp-1r激动剂的制剂及其制备方法
AU2024317579A1 (en) 2023-07-28 2026-02-05 Jiangsu Hansoh Pharmaceutical Group Co., Ltd. Benzo nitrogen-containing heterocyclic derivative regulator, preparation method therefor and use thereof
WO2025026436A1 (zh) * 2023-08-02 2025-02-06 韦恩生物科技有限公司 一种含氮并环化合物及其制备方法和用途
EP4771001A1 (en) * 2023-08-31 2026-07-08 Gasherbrum Bio, Inc. Heteroaryl-heterocycloalkyl-based glp-1 agonists
EP4777197A2 (en) 2023-09-14 2026-07-22 Ascletis Pharma (China) Co., Limited Glp-1r agonist and therapeutic method thereof
WO2025097835A1 (zh) 2023-11-10 2025-05-15 重庆医药工业研究院有限责任公司 一种glp-1r激动剂化合物及其应用
WO2025103443A1 (zh) * 2023-11-16 2025-05-22 海思科医药集团股份有限公司 一种咪唑-2-酮衍生物及其在医药上的应用
KR20260118441A (ko) 2023-11-21 2026-07-30 지앙수 헨그루이 파마슈티컬스 컴퍼니 리미티드 헤테로시클릭 화합물, 이의 제조 방법 및 의약에서 이의 응용
WO2025109387A1 (en) * 2023-11-24 2025-05-30 Ascletis Pharma (China) Co., Limited Glp-1r agonist and therapeutic method thereof
AU2024394361A1 (en) * 2023-12-05 2026-06-18 Fortvita Biologics Inc. Glp-1 receptor targeting compounds and uses thereof
CN122438847A (zh) * 2023-12-14 2026-07-21 广东众生睿创生物科技有限公司 一种杂环glp-1受体激动剂及其应用
WO2025131043A1 (zh) * 2023-12-22 2025-06-26 石药集团百克(山东)生物制药股份有限公司 一类多环化合物及其用途
CN117447493A (zh) * 2023-12-25 2024-01-26 药康众拓(北京)医药科技有限公司 氘代吲哚嗪类化合物、药物组合物及其应用
CN117777111A (zh) * 2023-12-26 2024-03-29 上海苏博医药科技有限公司 一种Orforglipron关键中间体的合成方法及其中间体
CN122514525A (zh) * 2024-01-10 2026-08-04 海思科医药集团股份有限公司 一种四氢吡啶并吡唑衍生物及其在医药上的应用
WO2025158275A1 (en) 2024-01-24 2025-07-31 Pfizer Inc. Combination therapy using glucose-dependent insulinotropic polypeptide receptor antagonist compounds and glp-1 receptor agonist compounds
CN120813584A (zh) * 2024-01-30 2025-10-17 海创药业股份有限公司 一种具有glp-1受体激动剂作用的小分子化合物及其用途
WO2025175249A1 (en) 2024-02-14 2025-08-21 Olema Pharmaceuticals, Inc. Estrogen receptor modulators and uses thereof
WO2025176130A1 (zh) * 2024-02-19 2025-08-28 上海壹迪生物技术有限公司 一种含吡唑并环类化合物、其药物组合物及其用途
TW202600132A (zh) 2024-03-08 2026-01-01 美商安尼波那生物公司 用於治療肥胖症及提高減重之方法
TW202602880A (zh) * 2024-03-29 2026-01-16 美商拜歐美亞富成股份有限公司 雜環glp-1r促效劑
WO2025209515A1 (zh) * 2024-04-03 2025-10-09 广州市联瑞制药有限公司 一种glp-1受体激动剂及其制备方法和应用
WO2025237355A1 (zh) * 2024-05-17 2025-11-20 成都地奥九泓制药厂 一种glp-1受体激动剂化合物、其制备方法及其应用
WO2025247390A1 (zh) * 2024-05-31 2025-12-04 福佑泰生物制药公司 可用作glp-1r激动剂的杂双环化合物
WO2025259825A1 (en) 2024-06-12 2025-12-18 Eli Lilly And Company Glp-1 npa therapies for maintaining body weight loss or reduced hba1c levels following a prior glp-1 ra treatment
WO2025261454A1 (zh) * 2024-06-19 2025-12-26 上海翰森生物医药科技有限公司 一种含氮大环化合物衍生物调节剂及其制备方法和应用
WO2025264023A1 (en) * 2024-06-19 2025-12-26 Chong Kun Dang Pharmaceutical Corp. Glp-1 receptor agonist, and uses thereof
WO2026001866A1 (zh) * 2024-06-24 2026-01-02 联邦生物科技(珠海横琴)有限公司 一种glp-1受体激动剂及其应用
WO2026007995A1 (zh) * 2024-07-03 2026-01-08 成都地奥九泓制药厂 一种杂环类glp-1受体激动剂化合物、其制备方法及其应用
WO2026012416A1 (zh) * 2024-07-11 2026-01-15 江苏德源药业股份有限公司 杂环类化合物、药物组合物及其应用
WO2026012449A1 (zh) * 2024-07-12 2026-01-15 联邦生物科技(珠海横琴)有限公司 一种具有glp-1受体激动剂效应的杂环化合物及其应用
WO2026031819A1 (en) * 2024-08-06 2026-02-12 Insilico Medicine Ip Limited Novel compounds as glp-1r agonists and uses thereof
WO2026041075A1 (en) * 2024-08-21 2026-02-26 Gasherbrum Bio, Inc. Gpl-1 agonists
CN119100966B (zh) * 2024-09-02 2025-09-09 上海毕得医药科技股份有限公司 一种溴代吡咯甲酸甲酯的合成方法
WO2026055512A1 (en) * 2024-09-05 2026-03-12 Biomea Fusion, Inc. Combination of a menin inhibitor with a pyrazolopiperidine glp-1 receptor agonist for treating diabetes and obesity
WO2026052129A1 (zh) * 2024-09-09 2026-03-12 中国科学院上海药物研究所 多环杂芳烃类glp-1受体激动剂
WO2026086876A1 (zh) * 2024-10-23 2026-04-30 郑州同源康医药有限公司 作为glp-1r激动剂的化合物
CN119372270A (zh) * 2024-10-25 2025-01-28 成都安迈博生物医药有限公司 一种通过酶催化构建Orforglipron吡喃环手性的方法
WO2026096330A1 (en) * 2024-10-28 2026-05-07 Merck Sharp & Dohme Llc Glp-1 receptor agonists and methods of use
WO2026092583A1 (en) 2024-10-30 2026-05-07 Ascletis Pharma (China) Co., Limited Thr-beta modulators, alone or in combination with glp-1r\gipr\gcgr modulators for the treatment of metabolic diseases and alopecia areata diseases
WO2026092580A1 (en) 2024-10-30 2026-05-07 Ascletis Pharma (China) Co., Limited Glp-1r\gipr\gcgr modulator in combination with thr-beta modulator for treatment of metabolic diseases
WO2026092581A1 (en) 2024-10-30 2026-05-07 Ascletis Pharma (China) Co., Limited Thyroid hormone receptor beta modulator alone or in combination with a modulator of glp-1r, gipr or gcgr, for use in the treatment of obesity or overweight or for treating alopecia areata
WO2026093542A1 (en) * 2024-11-01 2026-05-07 Astrazeneca Ab Glp1r agonist and sglt-2 inhibitor combination therapy
WO2026093539A1 (en) * 2024-11-01 2026-05-07 Astrazeneca Ab Methods of treating or managing obesity
WO2026093541A1 (en) * 2024-11-01 2026-05-07 Astrazeneca Ab Dosage regimens for azd5004
WO2026093537A1 (en) * 2024-11-01 2026-05-07 Astrazeneca Ab Methods of treating diabetes
WO2026093543A1 (en) * 2024-11-01 2026-05-07 Astrazeneca Ab Glp1r agonist and pcsk9 inhibitor combination therapy
CN119101040B (zh) 2024-11-08 2025-03-21 杭州澳赛诺医药技术有限公司 一种通过去对称化合成芳基取代的手性四氢吡喃环的方法
WO2026103930A1 (zh) * 2024-11-18 2026-05-21 西藏海思科制药有限公司 一种咪唑-2-酮衍生物及其在医药上的应用
WO2026130384A1 (zh) * 2024-12-17 2026-06-25 上海翰森生物医药科技有限公司 一种苯并含氮杂环类衍生物、其制备方法和应用
WO2026153543A1 (zh) * 2025-01-20 2026-07-23 歌礼制药(中国)有限公司 Glp-1r激动剂的晶型及其制备方法和用途
WO2026158353A1 (zh) * 2025-01-23 2026-07-30 联邦生物科技(珠海横琴)有限公司 具有glp-1受体激动剂效应的杂环化合物及其应用
WO2026158377A1 (zh) * 2025-01-24 2026-07-30 联邦生物科技(珠海横琴)有限公司 具有glp-1受体激动剂效应的杂环化合物及其应用
WO2026165082A1 (en) * 2025-01-28 2026-08-06 Ambrosia Biosciences Inc. Small molecule glp-1 agonists
CN120309500B (zh) * 2025-06-19 2025-08-15 南昌大学 奥格列龙原料中间体及合成方法与奥格列龙原料合成方法
CN121949295A (zh) * 2026-03-31 2026-05-01 成都安迈博生物医药有限公司 一种构建aleniglipron关键中间体的方法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
JP6278472B2 (ja) 2013-02-27 2018-02-14 塩野義製薬株式会社 Ampk活性化作用を有するインドールおよびアザインドール誘導体
JOP20190060A1 (ar) * 2016-09-26 2019-03-26 Chugai Pharmaceutical Co Ltd مشتق بيرازولو بيريدين له تأثير مساعد لمستقبل glp-1
JP7461104B2 (ja) * 2017-11-29 2024-04-03 中外製薬株式会社 Glp-1受容体アゴニスト作用を持つピラゾロピリジン誘導体を含有する医薬組成物
JP2021514982A (ja) 2018-02-28 2021-06-17 ノバルティス アーゲー インドール−2−カルボニル化合物及びb型肝炎治療のためのそれらの使用

Also Published As

Publication number Publication date
JP7795064B2 (ja) 2026-01-07
CA3186217A1 (en) 2022-01-27
JP2023534983A (ja) 2023-08-15
PH12023550130A1 (en) 2024-06-24
US20250059192A1 (en) 2025-02-20
AU2025237942A1 (en) 2025-10-16
US12037339B2 (en) 2024-07-16
AU2021311567B2 (en) 2025-07-10
CN122461300A (zh) 2026-07-28
CN116390926A (zh) 2023-07-04
CN122483082A (zh) 2026-07-31
CN122398793A (zh) 2026-07-17
CO2023001407A2 (es) 2023-02-16
IL299704B1 (en) 2026-07-01
US11584751B1 (en) 2023-02-21
UA130727C2 (uk) 2026-04-29
EP4182020A1 (en) 2023-05-24
AU2021311567A1 (en) 2023-02-16
CN122516176A (zh) 2026-08-07
JP2026035735A (ja) 2026-03-04
CN122398794A (zh) 2026-07-17
US20230051320A1 (en) 2023-02-16
CL2023000196A1 (es) 2023-09-15
MX2023000943A (es) 2023-02-22
BR112023000932A2 (pt) 2023-10-03
IL328692A (en) 2026-07-01
IL299704A (en) 2023-03-01
JP7569443B2 (ja) 2024-10-17
KR20230048056A (ko) 2023-04-10
WO2022017338A1 (en) 2022-01-27
CN116390926B (zh) 2026-05-19
CN122516177A (zh) 2026-08-07
CN122351233A (zh) 2026-07-10
JP2025004124A (ja) 2025-01-14
KR102936860B1 (ko) 2026-03-12
PE20230854A1 (es) 2023-05-29

Similar Documents

Publication Publication Date Title
KR102936860B1 (ko) 테트라히드로피라졸로-피라지닐-디히드로이미다졸론 또는 테트라히드로피라졸로-피리디닐-디히드로이미다졸론 화합물 및 그의 사용 방법
CN117222631A (zh) 苯基-[1,3]二氧杂环戊烯并[4,5-c]吡啶基-苯基-、苯基-[1,3]二氧杂环戊烯并[4,5-c]吡啶基-杂芳基-或苯基-[1,3]二氧杂环戊烯并[4,5-c]吡啶基-哌啶基-甲基-氧杂环丁烷基甲基-1h-苯并[d]咪唑-甲酸衍生物及其使用方法
EP4563199A2 (en) Gpcr receptor agonists, pharmaceutical compositions comprising the same, and methods for their use
CN112778276A (zh) 作为shp2抑制剂的化合物及其应用
CN109996541A (zh) N-酰基氨基酸化合物及其使用方法
TWI783205B (zh) 鹵代烯丙基胺類化合物及其用途
US20250326721A1 (en) Ssao inhibitors and use thereof
CN113754635B (zh) 稠环类化合物及其制备方法和用途
US11008317B2 (en) Triazolopyridine inhibitors of myeloperoxidase and/or EPX
JP2026502207A (ja) 硫黄/酸素置換グルタルイミジルイミドイソインドリノン骨格に基づいた化合物及びその応用
BR122025022209A2 (pt) Compostos de tetra-hidropirazolo-piridinil-di-hidroimidazolona, composição farmacêutica e seus usos
CA3199269A1 (en) Isoxazole derivatives as modulators of the 5-ht2a serotonin receptor useful for the treatment of disorders related thereto
EA049031B1 (ru) Соединения тетрагидропиразоло-пиразинил-дигидроимидазолона или тетрагидропиразоло-пиридинил-дигидроимидазолона и способы их применения
CN117800895A (zh) 草酸胺类衍生物、包含其的药物组合物及其医药用途
WO2026080493A1 (en) COMPOUNDS FOR THE TARGETED DEGRADATION OF PKA Cα
WO2026042788A1 (ja) 複素環誘導体
JP2025539873A (ja) Hur(elavl1)を調節するための化合物
HK40101057A (en) Bicyclic 1,4-diazepanones and therapeutic uses thereof
EA049321B1 (ru) Ингибиторы ssao и их применение
JPWO2020138015A1 (ja) ピラゾロ[1,5−a]ピリミジン大環状化合物

Legal Events

Date Code Title Description
A16 Divisional, continuation or continuation in part application filed

Free format text: ST27 STATUS EVENT CODE: A-0-1-A10-A16-DIV-PA0104 (AS PROVIDED BY THE NATIONAL OFFICE)

PA0104 Divisional application for international application

St.27 status event code: A-0-1-A10-A16-div-PA0104

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

Q12 Application published

Free format text: ST27 STATUS EVENT CODE: A-1-1-Q10-Q12-NAP-PG1501 (AS PROVIDED BY THE NATIONAL OFFICE)